Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Glucotrack (NASDAQ: GCTK) has announced the election of Victoria E. Carr-Brendel, PhD to its Board of Directors, effective May 22, 2025. Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, currently serving on Vicarious Surgical's board and previously leading Cochlear Implants at Sonova Group. She has held leadership positions at JenaValve Technology and Boston Scientific, with a career spanning roles at Dexcom and Baxter Healthcare.
Glucotrack is developing a long-term implantable Continuous Blood Glucose Monitoring (CBGM) system designed to function for up to three years without any wearable components. The system measures glucose directly from blood, aiming to provide real-time readings without the lag time associated with traditional interstitial fluid measurements. The device is currently in investigational status under U.S. law.
Glucotrack (NASDAQ: GCTK) ha annunciato l'elezione di Victoria E. Carr-Brendel, PhD nel suo Consiglio di Amministrazione, con decorrenza dal 22 maggio 2025. La dottoressa Carr-Brendel vanta una vasta esperienza nei dispositivi medici e nelle tecnologie impiantabili, attualmente fa parte del consiglio di Vicarious Surgical e in precedenza ha guidato la divisione di impianti cocleari presso Sonova Group. Ha ricoperto ruoli di leadership presso JenaValve Technology e Boston Scientific, con una carriera che include posizioni in Dexcom e Baxter Healthcare.
Glucotrack sta sviluppando un sistema di monitoraggio continuo del glucosio nel sangue (CBGM) impiantabile a lungo termine, progettato per funzionare fino a tre anni senza componenti indossabili. Il sistema misura il glucosio direttamente dal sangue, con l'obiettivo di fornire letture in tempo reale senza il ritardo tipico delle misurazioni tradizionali nel fluido interstiziale. Il dispositivo è attualmente in fase di sperimentazione secondo la normativa statunitense.
Glucotrack (NASDAQ: GCTK) ha anunciado la elección de Victoria E. Carr-Brendel, PhD para su Junta Directiva, con efecto a partir del 22 de mayo de 2025. La Dra. Carr-Brendel aporta amplia experiencia en dispositivos médicos y tecnologías implantables, actualmente forma parte del consejo de Vicarious Surgical y anteriormente lideró el área de implantes cocleares en Sonova Group. Ha ocupado cargos de liderazgo en JenaValve Technology y Boston Scientific, con una carrera que incluye roles en Dexcom y Baxter Healthcare.
Glucotrack está desarrollando un sistema implantable de monitoreo continuo de glucosa en sangre (CBGM) a largo plazo, diseñado para funcionar hasta tres años sin componentes portátiles. El sistema mide la glucosa directamente en la sangre, con el objetivo de proporcionar lecturas en tiempo real sin el retraso asociado a las mediciones tradicionales en el líquido intersticial. El dispositivo se encuentra actualmente en estado investigacional bajo la legislación estadounidense.
Glucotrack (NASDAQ: GCTK)는 2025년 5월 22일부터 효력이 발생하는 Victoria E. Carr-Brendel, PhD를 이사회 멤버로 선임했다고 발표했습니다. Carr-Brendel 박사는 의료기기 및 이식 기술 분야에서 풍부한 경험을 갖고 있으며, 현재 Vicarious Surgical 이사회에서 활동 중이고 이전에는 Sonova Group에서 인공 와우 이식 부서를 이끌었습니다. 또한 JenaValve Technology와 Boston Scientific에서 리더십 역할을 수행했으며, Dexcom과 Baxter Healthcare에서도 경력을 쌓았습니다.
Glucotrack은 장기간 이식 가능한 연속 혈당 모니터링(CBGM) 시스템을 개발 중이며, 착용 부품 없이 최대 3년간 작동하도록 설계되었습니다. 이 시스템은 전통적인 간질액 측정에서 발생하는 지연 없이 혈액에서 직접 포도당을 측정하여 실시간 수치를 제공하는 것을 목표로 합니다. 이 장치는 현재 미국 법률에 따라 임상 시험 단계에 있습니다.
Glucotrack (NASDAQ : GCTK) a annoncé l'élection de Victoria E. Carr-Brendel, PhD à son conseil d'administration, effective à compter du 22 mai 2025. Dr Carr-Brendel apporte une vaste expérience dans les dispositifs médicaux et les technologies implantables, siégeant actuellement au conseil de Vicarious Surgical et ayant précédemment dirigé les implants cochléaires chez Sonova Group. Elle a occupé des postes de direction chez JenaValve Technology et Boston Scientific, avec une carrière incluant des rôles chez Dexcom et Baxter Healthcare.
Glucotrack développe un système de surveillance continue du glucose sanguin (CBGM) implantable à long terme, conçu pour fonctionner jusqu'à trois ans sans composants portables. Le système mesure le glucose directement dans le sang, visant à fournir des lectures en temps réel sans le délai associé aux mesures traditionnelles du liquide interstitiel. Le dispositif est actuellement en phase d'investigation selon la législation américaine.
Glucotrack (NASDAQ: GCTK) hat die Wahl von Victoria E. Carr-Brendel, PhD in den Vorstand mit Wirkung zum 22. Mai 2025 bekannt gegeben. Dr. Carr-Brendel bringt umfangreiche Erfahrung im Bereich medizinischer Geräte und implantierbarer Technologien mit, ist derzeit im Vorstand von Vicarious Surgical tätig und leitete zuvor die Cochlea-Implantate bei der Sonova Group. Sie hatte Führungspositionen bei JenaValve Technology und Boston Scientific inne und war außerdem bei Dexcom und Baxter Healthcare tätig.
Glucotrack entwickelt ein langfristig implantierbares System zur kontinuierlichen Blutzuckermessung (CBGM), das bis zu drei Jahre ohne tragbare Komponenten funktionieren soll. Das System misst den Glukosespiegel direkt im Blut und zielt darauf ab, Echtzeitwerte ohne die Verzögerung herkömmlicher Messungen im interstitiellen Flüssigkeitsraum zu liefern. Das Gerät befindet sich derzeit im Untersuchungsstatus gemäß US-Recht.
- Addition of experienced medical device executive with expertise in implantable technologies to the board
- Dr. Carr-Brendel brings valuable experience from leadership roles at Sonova Group, JenaValve, Boston Scientific, and Dexcom
- Her expertise aligns with Glucotrack's focus on implantable glucose monitoring technology
- CBGM system is still in investigational phase, with no immediate revenue generation
- Regulatory approval timeline remains uncertain
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company’s Board of Directors, effective May 22, 2025.
“We are delighted to welcome Dr. Carr-Brendel to Glucotrack’s Board of Directors,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monitoring (CBGM) technology through clinical development and move closer to commercialization.”
Dr. Carr-Brendel currently serves as a member of the board of directors of Vicarious Surgical Inc. (NYSE: RBOT) since January 2023 and previously served from 2018 to 2024 as President and Group Vice President of Cochlear Implants at Sonova Group. Prior to that, she served as Chief Executive Officer of JenaValve Technology, Inc., a medical device company focused on developing minimally invasive transcatheter aortic valve repair systems for patients suffering from severe aortic valve disease. Previously, Dr. Carr-Brendel held various leadership roles at Boston Scientific, including overseeing the acquisition of Bayer’s interventional radiology division in 2014. She started her career as a scientist in R&D with roles at Dexcom and Baxter Healthcare, amassing over forty patents and taking on increasingly senior business and management roles. She holds a BA in Biology from Monmouth College, an MS in Microbiology from Iowa State University, and a PhD in Microbiology and Immunology from the University of Illinois at Chicago.
“I am honored to be joining Glucotrack’s Board of Directors at this pivotal time in the company’s development,” said Victoria E. Carr-Brendel, PhD. “The innovative CBGM has tremendous potential to address significant unmet needs for people with diabetes and enhance automated insulin delivery. I look forward to contributing to the Company as it works to achieve its strategic and clinical milestones.”
Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information about Glucotrack’s CBGM technology, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
Who is Victoria Carr-Brendel and why did Glucotrack (GCTK) appoint her to the board?
What is Glucotrack's (GCTK) main product under development?
How is Glucotrack's (GCTK) CBGM different from traditional glucose monitors?
What is the current status of Glucotrack's (GCTK) CBGM device?
